First quarter sales of Hi-Tech Pharmacal's fluticasone proprionate nasal spray rose from $11,700,000 in 2010 to $26,200,000 this year, the company has announced, continuing a rapid increase in sales since the product was introduced. First quarter earnings rose 59% overall, which is mostly attributable to the increase in nasal spray sales. The fluticasone … [Read more...] about Hi-Tech Pharmacal’s fluticasone nasal spray sales more than double
News
Freeman Technology moves to new facility
Freeman Technology has moved to a new, larger facility in the Tewkesbury Business Park in Gloucestershire, UK. The new building includes office, laboratory, and manufacturing areas; additional space for expansion is available. Freeman has been actively working to expand its powder characterization instrument business, focusing on the FT4 Powder rheometer, which can … [Read more...] about Freeman Technology moves to new facility
Xcelience adds capacity for clinical trial supplies for DPIs
Contract drug developer Xcelience has added micro-dosing capacity for the manufacturing of clinical supplies for dry powder inhaler delivery systems. The addition of an MG Futura capsule filler, says the company, "improves upon production times, increases overall capacity, and expands upon our existing capabilities for powders, pellets and powder micro-dosing for … [Read more...] about Xcelience adds capacity for clinical trial supplies for DPIs
Iran phases out CFC inhalers
On September 5, a ceremony in Tehran marked the occasion as Iran officially phased out CFC-based metered dose inhalers (MDIs) in accordance with the Montreal Protocol, becoming the first country in the Asia-Pacific region to do so. The event, attended by government officials, clinicians, and representatives of international organizations, celebrated the closing of … [Read more...] about Iran phases out CFC inhalers
Bespak enters nasal drug delivery market
UK drug delivery device company Bespak, a division of Consort Medical, says that it will develop a nasal delivery device "for a major unnamed global pharmaceutical company." The contract, Bespak's first for a nasal device, involves development of a device for an undisclosed product that the pharmaceutical company plans to launch in 2015. Bespak sells more than 500 … [Read more...] about Bespak enters nasal drug delivery market
A new model for vapor deposition in the lung
A group of researchers funded by the Research Institute for Fragrance Materials (RIFM) have developed a new model for vapor deposition in the lung and have published their work in an article titled "Derivation of Mass Transfer Coefficients for Transient Uptake and Tissue Disposition of Soluble and Reactive Vapors in Lung Airways," published in the June 2011 issue of … [Read more...] about A new model for vapor deposition in the lung
NEJM editorial praises move towards personalized asthma treatment
An editorial by Monica Kraft in the August 31 online version of the New England Journal of Medicine voices approval for a recent article in the journal describing a study of lebrikizumab treatment for asthma patients whose disease was not well controlled with inhaled glucocorticoids. Lebrikizumab is a monoclonal antibody to interleukin-13, and the study found an … [Read more...] about NEJM editorial praises move towards personalized asthma treatment
Latest update on acetylcysteine inhalation solution shortage
According to the FDA's latest update on the ongoing acetylcysteine inhalation solution shortage, all of American Regent/Luitpold's product is still on back order due to "manufacturing delays," and the company is still unable to estimate a release date for any inhalation solution. The company's Shirley, NY facility was shut down in April 2011 over safety concerns. … [Read more...] about Latest update on acetylcysteine inhalation solution shortage
Positive Phase 2b results for Pearl Therapeutics MDI
A randomized, double-blind, Phase 2b dose-ranging study of Pearl Therapeutics' formoterol fumarate MDI compared to Foradil Aerolizer and placebo showed statistically significant benefits in patients with moderate-to-severe COPD, according to the company. The metered dose inhaler product, known as PT005, demonstrated comparable improvements in lung function compared to … [Read more...] about Positive Phase 2b results for Pearl Therapeutics MDI
Gateway Analytical’s quality management system now ISO accredited
Contract research company Gateway Analytical has received certification under ISO standard 9001:2008 for its analytical laboratory process quality management system. The laboratory, which provides ingredient-specific particle sizing for nasal sprays and inhalers among other services, began operations at its Gibsonia, PA facility in October 2010. Senior VP David … [Read more...] about Gateway Analytical’s quality management system now ISO accredited